Prevalence and factors associated with web‑like mucus in the stomach after vonoprazan use

Shinozaki,Satoshi; Sakamoto,Hirotsugu; Osawa,Hiroyuki; Yano,Tomonori; Yamamoto,Hironori

doi:10.3892/br.2024.1911

Prevalence and factors associated with web‑like mucus in the stomach after vonoprazan use

Authors:
- Satoshi Shinozaki
- Hirotsugu Sakamoto
- Hiroyuki Osawa
- Tomonori Yano
- Hironori Yamamoto
View Affiliations

Affiliations: Shinozaki Medical Clinic, Utsunomiya, Tochigi 321‑3223, Japan, Division of Gastroenterology, Department of Medicine, Jichi Medical University, Shimotsuke, Tochigi 329‑0498, Japan
Published online on: December 10, 2024 https://doi.org/10.3892/br.2024.1911
Article Number: 33
Copyright: © Shinozaki et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The appearance of ‘web‑like mucus’ in the stomach is a novel phenomenon associated with vonoprazan (VPZ) usage, characterized by a descriptive mucus pattern resembling a spider web or net. The present study aimed to determine its prevalence and related factors. In this retrospective observational study, the medical records and endoscopic reports of 547 patients who underwent an esophagogastroduodenoscopy were reviewed. The overall prevalence of web‑like mucus was 6% (33/547), with 97% (32/33) of these patients being VPZ users. Specifically, 19% (32/167) of VPZ users exhibited this web‑like mucus pattern, which was significantly more prevalent in the VPZ group than in the control (no acid blocker intake), proton pump inhibitor, and histamine‑2 receptor antagonist groups. Multivariate analysis identified that VPZ use was positively associated with web‑like mucus, while open‑type gastric atrophy and multiple white and flat elevated lesions were negatively associated. A retrospective analysis of endoscopic findings before initiating VPZ therapy showed that none of the 32 VPZ users with web‑like mucus had exhibited the pattern previously. Furthermore, the Cochran‑Armitage trend test indicated no significant association between the duration of VPZ therapy and the prevalence of web‑like mucus. In conclusion, web‑like mucus in the stomach is strongly associated with VPZ use but is not associated with the duration of VPZ therapy.

View Figures

View References

1	Yamamichi N, Shimamoto T, Takahashi Y, Takahashi M, Takeuchi C, Wada R and Fujishiro M: Trends in proton pump inhibitor use, reflux esophagitis, and various upper gastrointestinal symptoms from 2010 to 2019 in Japan. PLoS One. 17(e0270252)2022.PubMed/NCBI View Article : Google Scholar
2	Iwakiri K, Fujiwara Y, Manabe N, Ihara E, Kuribayashi S, Akiyama J, Kondo T, Yamashita H, Ishimura N, Kitasako Y, et al: Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2021. J Gastroenterol. 57:267–285. 2022.PubMed/NCBI View Article : Google Scholar
3	GBD 2017 Gastro-oesophageal Reflux Disease Collaborators. The global, regional, and national burden of gastro-oesophageal reflux disease in 195 countries and territories, 1990-2017: A systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 5:561–581. 2020.PubMed/NCBI View Article : Google Scholar
4	Yoshizaki T, Morisawa T, Fujinami M, Matsuda T, Katayama N, Inoue K, Matsumoto M, Ikeoka S, Takagi M, Sako T, et al: Propensity score matching analysis: Incidence and risk factors for ‘stardust’ gastric mucosa, a novel gastric finding potentially induced by vonoprazan. Aliment Pharmacol Ther. 53:94–102. 2021.PubMed/NCBI View Article : Google Scholar
5	Shinozaki S, Osawa H, Miura Y, Nomoto H, Sakamoto H, Hayashi Y, Yano T, Despott EJ and Yamamoto H: Endoscopic findings and outcomes of gastric mucosal changes relating to potassium-competitive acid blocker and proton pump inhibitor therapy. DEN Open. 5(e400)2024.PubMed/NCBI View Article : Google Scholar
6	Kubo K, Kimura N and Kato M: Potassium-competitive acid blocker-associated gastric mucosal lesions. Clin Endosc. 57:417–423. 2024.PubMed/NCBI View Article : Google Scholar
7	Kaneko H, Sato H, Suzuki Y, Ikeda A, Kuwashima H, Ikeda R, Sato T, Irie K, Sue S and Maeda S: A novel characteristic gastric mucus named ‘Web-like Mucus’ potentially induced by vonoprazan. J Clin Med. 13(4070)2024.PubMed/NCBI View Article : Google Scholar
8	Kimura K and Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy. 1:87–97. 1969.
9	Skoczylas T, Sarosiek I, Sostarich S, McElhinney C, Durham S and Sarosiek J: Significant enhancement of gastric mucin content after rabeprazole administration: Its potential clinical significance in acid-related disorders. Dig Dis Sci. 48:322–328. 2003.PubMed/NCBI View Article : Google Scholar
10	Kinoshita Y, Haruma K, Yao T, Kushima R, Akiyama J, Kanoo T, Miyata K, Kusumoto N and Uemura N: Ep54 Final Observation Results of Vision Trial: A Randomized, Open-Label Study to Evaluate the Long-Term Safety of Vonoprazan as Maintenance Treatment in Patients with Erosive Esophagitis. Gastroenterology. 164:S–1202. 2023.
11	Shinozaki S, Osawa H, Miura Y, Hayashi Y, Sakamoto H, Yano T, Lefor AK and Yamamoto H: Long-term changes in serum gastrin levels during standard dose vonoprazan therapy. Scand J Gastroenterol. 57:1412–1416. 2022.PubMed/NCBI View Article : Google Scholar
12	Shiotani A, Katsumata R, Gouda K, Fukushima S, Nakato R, Murao T, Ishii M, Fujita M, Matsumoto H and Sakakibara T: Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors. Digestion. 97:154–162. 2018.PubMed/NCBI View Article : Google Scholar
13	Niv Y and Boltin D: Secreted and membrane-bound mucins and idiopathic peptic ulcer disease. Digestion. 86:258–263. 2012.PubMed/NCBI View Article : Google Scholar
14	Sakai T, Ishihara K, Saigenji K and Hotta K: Recovery of mucin content in surface layer of rat gastric mucosa after HCl-aspirin-induced mucosal damage. J Gastroenterol. 32:157–163. 1997.PubMed/NCBI View Article : Google Scholar
15	Lanas Á, Carrera-Lasfuentes P, Arguedas Y, García S, Bujanda L, Calvet X, Ponce J, Perez-Aísa Á, Castro M, Muñoz M, et al: Risk of upper and lower gastrointestinal bleeding in patients taking nonsteroidal anti-inflammatory drugs, antiplatelet agents, or anticoagulants. Clin Gastroenterol Hepatol. 13:906–912.e902. 2015.PubMed/NCBI View Article : Google Scholar
16	Blandizzi C, Gherardi G, Marveggio C, Natale G, Carignani D and Del Tacca M: Mechanisms of protection by omeprazole against experimental gastric mucosal damage in rats. Digestion. 56:220–229. 1995.PubMed/NCBI View Article : Google Scholar
17	Kawai T, Oda K, Funao N, Nishimura A, Matsumoto Y, Mizokami Y, Ashida K and Sugano K: Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: Randomised phase 3 study. Gut. 67:1033–1041. 2018.PubMed/NCBI View Article : Google Scholar
18	Lombardo L, Foti M, Ruggia O and Chiecchio A: Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol. 8:504–508. 2010.PubMed/NCBI View Article : Google Scholar
19	Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W and Stockbrügger RW: Non-Helicobacter pylori bacterial flora during acid-suppressive therapy: Differential findings in gastric juice and gastric mucosa. Aliment Pharmacol Ther. 15:379–388. 2001.PubMed/NCBI View Article : Google Scholar
20	Minalyan A, Gabrielyan L, Scott D, Jacobs J and Pisegna JR: The gastric and intestinal microbiome: Role of proton pump inhibitors. Curr Gastroenterol Rep. 19(42)2017.PubMed/NCBI View Article : Google Scholar